The world of cancer research is abuzz with an exciting announcement! IARC, a renowned global authority in cancer research, has chosen The Lancet, a prestigious medical journal, as its partner for a monumental conference. This collaboration is a significant milestone in the realm of medical research and publishing, and it's sure to capture the attention of the scientific community.
But here's where it gets even more intriguing: The Lancet will contribute through its esteemed journals, including The Lancet Oncology, The Lancet Public Health, and eClinicalMedicine. Imagine the impact when these powerhouses join forces! A special issue of eClinicalMedicine will showcase abstracts handpicked by Lancet editors, offering a glimpse into the conference's potential.
The conference, IARC@60: Cancer Research into Action, will be a three-day event from May 19-21, 2026, in Lyon, France. It promises to be an intellectual feast, covering critical themes: from cancer prevention discoveries to translating research into actionable public health measures and exploring the science-policy interface for global change. And this is the part most researchers won't want to miss—the deadline for abstract submissions is January 12, 2026.
This conference is not just a celebration of IARC's 60th anniversary but a testament to the power of collaboration in advancing cancer research. It's a platform for scientists, researchers, and medical professionals to exchange ideas and shape the future of cancer prevention and treatment.
What are your thoughts on this partnership? Do you think collaborations like these accelerate medical advancements? Share your opinions below, and let's spark a conversation about the role of partnerships in scientific progress!
